MedTrace Logo

A Study of 19-28z/IL-18 in People With Acute Lymphoblastic Leukemia (ALL)

NCT06287528 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2026-02-10

No results posted yet for this study

Summary

Participants will have a sample of their white blood cells, called T cells, collected using a procedure called leukapheresis. The collected T cells will be sent to a laboratory to be changed (modified) to become 19-28z/IL-18, the CAR T-cell therapy that participants will receive during the study. Making the participants' study therapy will take about 2-4 weeks.

Conditions

  • Philadelphia-Negative ALL
  • Philadelphia-Positive ALL
  • Relapsed ALL, Adult
  • Refractory Acute Lymphoblastic Leukemia
  • Refractory Acute Lymphoblastic Leukemia (ALL)
  • Refractory Acute Lymphoid Leukemia in Relapse

Interventions

BIOLOGICAL

19-28z/IL-18 CAR T cells

19-28z/IL-18 CAR T cells are an investigational new drug (IND) for the treatment of R/R B-ALL

Sponsors & Collaborators

Principal Investigators

  • Jae Park, MD · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-02-23
Primary Completion
2028-02-23
Completion
2028-02-23
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06287528 on ClinicalTrials.gov